Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
 |
Seattle’s Pharma Godfather, Ben Shapiro, Sees Potential Here To Transform Medicine Despite Setbacksxconomy.com » Xconomy Venture Capital Feed - Nov 18, 2008 Biotech, Merck, University of Washington Luke Timmerman wrote: Not many people in the world have played a leading role in delivering 23 new drugs and vaccines to the U.S. market. Bennett Shapiro is the only person … Also tagged: aids, obesity, seattle, biotech, vc, mit, pain, biochemistry, university of washington, amgen, gardasil, merck, alzheimer s, icos, magnolia, vioxx, national institutes of health, puget sound, accelerator, life sciences, rheumatoid arthritis, fred hutchinson cancer research center, enbrel, ikaria, mark roth, celera, san juan islands, national blog main, seattle blog main, arch venture partners, carl weissman, elixir pharmaceuticals, bob nelsen, fate therapeutics, immunex, bennett shapiro, drugs for neglected diseases initiative, olympic mountains, mind and 38 life institute, vascular biogenics |
|
Seattle’s Pharma Godfather, Ben Shapiro, Sees Potential Here To Transform Medicine Despite Setbacksxconomy.com » Xconomy Seattle - Nov 17, 2008 Biotech, Merck, University of Washington Luke Timmerman wrote: Not many people in the world have played a leading role in delivering 23 new drugs and vaccines to the U.S. market. Bennett Shapiro is the only person … Also tagged: aids, obesity, seattle, biotech, vc, mit, pain, biochemistry, university of washington, amgen, gardasil, merck, alzheimer s, icos, magnolia, vioxx, national institutes of health, puget sound, accelerator, life sciences, rheumatoid arthritis, fred hutchinson cancer research center, enbrel, ikaria, mark roth, celera, san juan islands, national blog main, seattle blog main, arch venture partners, carl weissman, elixir pharmaceuticals, bob nelsen, fate therapeutics, immunex, bennett shapiro, drugs for neglected diseases initiative, olympic mountains, mind and 38 life institute, vascular biogenics |
 |
How Bad is the Biotech Climate? Think 4 on a Scale of 10xconomy.com » Xconomy - Nov 5, 2008 Biotech, VC, management Robert Buderi wrote: The climate for biotechnology companies in Massachusetts today is 33 percent worse than it was this time last year—rating a ‘4′ on a scale of 10, in contrast to the ‘6′ … Also tagged: drugs, people, management, biotech, vc, boston, john edwards, life sciences, polaris venture partners, boston blog main, national blog main, adnexus therapeutics, massachusetts biotechnology council, ernst and 38 young, deals startups, gautam jaggi, eric elenko, mark kessel, kevin j bitterman, symphony capital |
|
How Bad is the Biotech Climate? Think 4 on a Scale of 10xconomy.com » Xconomy Boston - Nov 4, 2008 Biotech, VC, management Robert Buderi wrote: The climate for biotechnology companies in Massachusetts today is 33 percent worse than it was this time last year—rating a ‘4′ on a scale of 10, in contrast to the ‘6′ … Also tagged: drugs, people, management, biotech, vc, boston, john edwards, life sciences, polaris venture partners, boston blog main, national blog main, adnexus therapeutics, massachusetts biotechnology council, ernst and 38 young, deals startups, gautam jaggi, eric elenko, mark kessel, kevin j bitterman, symphony capital |
xconomy.com » Xconomy Life Sciences Feed - Oct 25, 2008
deals, Biotech, startups Rebecca Zacks wrote: Mersana Therapeutics has completed a convertible note placement worth $4 million, officials of the Cambridge, MA-based cancer drug developer told Mass High Tech. The new …
Also tagged: drugs, biotech, vc, boston, deals, startups, boston briefs, fidelity biosciences, rho ventures, mersana therapeutics, harris and 38 harris group, proquest investments
xconomy.com » Xconomy Venture Capital Feed - Oct 24, 2008
deals, Biotech, startups Rebecca Zacks wrote: Mersana Therapeutics has completed a convertible note placement worth $4 million, officials of the Cambridge, MA-based cancer drug developer told Mass High Tech. The new …
Also tagged: drugs, biotech, vc, boston, deals, startups, boston briefs, fidelity biosciences, rho ventures, mersana therapeutics, harris and 38 harris group, proquest investments
xconomy.com » Xconomy Energy Feed - Sep 28, 2008
Roundup, deals, startups Rebecca Zacks wrote: Last week was a quiet one for New England tech and life sciences firms, but there was a steady stream of small deals nonetheless. —Boston-based Follica, which is …
Also tagged: energy, software, roundup, biotech, vc, boston, deals, segway, startups, university of washington, new enterprise associates, hewlett packard, life sciences, cleantech, axi, polaris venture partners, lockheed martin corporation, interwest partners, boston blog main, nantero, national blog main, voltan biofuel, patientkeeper, follica, nitrosecurity, frazier healthcare ventures, allied minds, colubris networks, newspring ventures
xconomy.com » Xconomy Boston - Sep 26, 2008
Biotech, Life Sciences, events Ryan McBride wrote: We could have called it the “New Biotech Business Model Expo.” Xconomy’s forum—How to Build a Life Sciences Company—attracted venture capitalists and entrepreneurs …
Also tagged: events, people, biotech, boston, mit, novartis, david steinberg, north bridge venture partners, life sciences, polaris venture partners, myer berlow, boston blog main, national blog main, fate therapeutics, alex rives, amir nashat, carmichael roberts, rxi pharmaceuticals, enlight biosciences, tod woolf, david schubert, terry mcguire, quanterix, david walt, bob langer, accelerator corp, nano terra, chuck wilson, nicholas naclerio
xconomy.com » Xconomy Life Sciences Feed - Sep 25, 2008
Biotech, Life Sciences, events Ryan McBride wrote: We could have called it the “New Biotech Business Model Expo.” Xconomy’s forum—How to Build a Life Sciences Company—attracted venture capitalists and entrepreneurs …
Also tagged: events, people, biotech, boston, mit, novartis, david steinberg, north bridge venture partners, life sciences, polaris venture partners, myer berlow, boston blog main, national blog main, fate therapeutics, alex rives, amir nashat, carmichael roberts, rxi pharmaceuticals, enlight biosciences, tod woolf, david schubert, terry mcguire, quanterix, david walt, bob langer, accelerator corp, nano terra, chuck wilson, nicholas naclerio
xconomy.com » Xconomy - Aug 19, 2008
Roundup, deals, startups Rebecca Zacks wrote: Last week was a quiet one for New England tech and life sciences firms, but there was a steady stream of small deals nonetheless. —Boston-based Follica, which is …
Also tagged: energy, software, roundup, biotech, vc, boston, deals, segway, startups, university of washington, new enterprise associates, hewlett packard, life sciences, cleantech, axi, polaris venture partners, lockheed martin corporation, interwest partners, boston blog main, nantero, national blog main, voltan biofuel, patientkeeper, follica, nitrosecurity, frazier healthcare ventures, allied minds, colubris networks, newspring ventures